Delcath Systems

Youtube Subscribe

Open: 5.39 Close: 5.13 Change: -0.26

You'll be sorry if you don't use an AI to decide whether to invest in Delcath Systems.

Are looking for the most relevant information about Delcath Systems? Investor spend a lot of time searching for information to make investment decisions in Delcath Systems. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Delcath Systems are: Systems, Delcath, decrease, DelcATH, StockNewscom, upgrade, sell, and the most common words in the summary are: therapeutic, pharmaceutical, system, inc, delcath, nasdaq, state, . One of the sentences in the summary was: new drug application resubmission.. Other searches related to this term that …

Concept Map

Semantic Network

Stock Summary

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. Its lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection.

Today's Summary

StockNews.com upgraded Delcath Systems from a “sell” rating to a ‘hold” in a research report on Friday, May 26th. HC Wainwright decreased their target price on DelcATH Systems from $19.00 to $17.00. In the year 2022, Delcath Systems had annual revenue of $2.72M, a decrease of -23.52%. In the U.S. Food and Drug Administration (FDA) has accepted DelcATH Systems, Inc. new drug application resubmission.

Today's News

StockNews.com upgraded Delcath Systems from a “sell” rating to a ‘hold” in a research report on Friday, May 26th. HC Wainwright decreased their target price on DelcATH Systems from $19.00 to $17.00. In the year 2022, Delcath Systems had annual revenue of $2.72M, a decrease of -23.52%. In the U.S. Food and Drug Administration (FDA) has accepted DelcATH Systems, Inc. new drug application resubmission.

Stock Profile

"Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York."

Keywords

The game is changing. There is a new strategy to evaluate Delcath Systems fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Delcath Systems are: Systems, Delcath, decrease, DelcATH, StockNewscom, upgrade, sell, and the most common words in the summary are: therapeutic, pharmaceutical, system, inc, delcath, nasdaq, state, . One of the sentences in the summary was: new drug application resubmission.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #system #inc #delcath #nasdaq #state.

Read more →

Youtube Subscribe

---